Synthesis of fluorinated 2,3-disubstituted benzofurans potential β-amyloid aggregation inhibitors

Article abstract of DOI:10.3987/COM-09-S(S)59

A convenient synthesis of 2-[4'-(3-diethylaminopropoxy)phenyl]-3(2-fluorobenzoyl)benzofuran, 3-(4-fluorobenzoyl)- and 3-(4-trifluoromethylbenzoyl) derivatives, via the Suzuki cross-coupling reaction as the key transformation, is described.

Full text of DOI:10.3987/COM-09-S(S)59

HETEROCYCLES, Vol. 80, No. 1, 2010
663
HETEROCYCLES, Vol. 80, No. 1, 2010, pp. 663 - 668. © The Japan Institute of Heterocyclic Chemistry
Received, 17th July, 2009, Accepted, 18th August, 2009, Published online, 20th August, 2009
DOI: 10.3987/COM-09-S(S)59
SYNTHESIS OF FLUORINATED 2,3-DISUBSTITUTED BENZOFURANS
POTENTIAL -AMYLOID AGGREGATION INHIBITORS#
Marek Zaidlewicz,a* Tomasz Kosmalski,a Tathagata Sengupta,b
Kochupurackal P. Mohanakumar,b and Krzysztof Staszaka
aFaculty of Chemistry, Nicolaus Copernicus University, 7 Gagarin Street, 87-100
Torun, Poland
bIndian Institute of Chemical Biology (CSIR, Govt. of India), 4 Raja S. C. Mullick
Road, Kolkata 700032, India
zaidlevi@chem.uni.torun.pl
Abstract – A convenient synthesis of 2-[4’-(3-diethylaminopropoxy)phenyl]-3-
(2-fluorobenzoyl)benzofuran, 3-(4-fluorobenzoyl)- and 3-(4-trifluoromethyl-
benzoyl) derivatives, via the Suzuki cross-coupling reaction as the key trans-
formation, is described.
#Dedicated to Professor Akira Suzuki on the occasion of his 80th birthday.
Aggregated -amyloid peptides are components of the intracellular neurofibrillary tangles of senile pla-
ques in Alzheimer’s disease brain.1-4 For symptomatic treatment acetylcholine esterase inhibitors, e.g.
donepezil, rivastigmine, or galantamine, are used,5,6 and new compounds are under investigation,7 to in-
crease acetylcholine levels in the brain thereby improving cholinergic neurotransmission.5,6 Among other
approaches to Alzheimer’s disease therapy, inhibitors of -amyloid aggregation are studied.8
Recently, benzofuran derivatives 1, 2, their 3-benzoyl and 3-tolyl derivatives were shown to be inhibitors
of -amyloid fibrils formation.9-11 The observed structure activity relationships prompted us to undertake
the synthesis of 2-[4’-(3-diethylaminopropoxy)phenyl]-3-(2-fluorobenzoyl)benzofuran (3), 3-(4-
fluorobenzoyl), and 3-(4-trifluoromethylbenzoyl) derivatives 4, 5 (Scheme 1), since the introduction of
fluorine often exerts an effect on the physiological activity of compounds, exemplified by many fluori-
nated drugs.5

664
HETEROCYCLES, Vol. 80, No. 1, 2010
Ar
O
O
O(CH2)nNR1R2
O(CH2)3NEt2
1, n = 3, R1,R2 = Et
2, n = 7, R1 = Me, R2 = Bn
3, Ar = 2-FC6H4CO
4, Ar = 4-FC6H4CO
5, Ar = 4-CF3C6H4CO
Scheme 1
Although the compounds 3–5 could be prepared via earlier approaches to the synthesis of non-fluorinated
compounds, involving classical non-catalytic transformations,9,12,13 we decided to introduce the aryl subs-
tituent in the 2-position of benzofuran by the Suzuki cross-coupling reaction. Thus, 2-
benzofuranylboronic acid (6),14 was treated with 4-(3-diethylaminopropoxy)bromobenzene (7) in the
presence of palladium acetate, potassium carbonate, in tetrahydrofuran–water, however, under these con-
ditions the coupling product was not obtained. Attempted coupling of 7 with more reactive cyclic triolbo-
rates, prepared from 6 following the reported general procedure,15 was also unsuccessful.
Consequently, the synthesis was modified to prepare 2-(4-methoxyphenyl)benzofuran 8 by the cross-
coupling reaction of 6 with 4-iodoanisole. Two reported reaction conditions,16,17 developed for the reac-
tion of various aryl iodides and bromides with arylboronic acids, have been tested. The catalytic system,
palladium acetate/DABCO, in the presence of potassium carbonate in acetone at 110 °C, produced the
coupling product in low yield. Fortunately, under the second reaction conditions, palladium acetate, po-
tassium carbonate in polyethylene glycol 4000–methanol,17 the reaction produced 8 in 94% yield
(Scheme 2). Isolation of the product is simple and does not require chromatographic separation or purifi-
cation. The reaction works also when water is used instead of methanol, although it is less convenient.
Earlier, 8 was prepared by the Suzuki reaction of 6 with 4-bromoanisole in a microwave-assisted reaction,
90% yield,18 and also with tetrafluoroborate diazonium salt, generated from 4-bromoaniline, 61% yield.19
It should be noted that under conditions used for the synthesis of 8 no cross-coupling of 6 with 4-(3-
diethylaminopropoxy)bromobenzene (7) was observed. Apparently, either lower reactivity of the aryl
bromide moiety, or deactivation of the catalyst by the amino group prevents the reaction.
In the next step, the Friedel-Crafts acylation of 8 with 4-fluorobenzoyl chloride in the presence of tin(IV)
chloride in dichlomethane produced the corresponding fluoroketone 9 in 85% yield. The methoxy group
of 9 was cleaved with boron tribromide at room temperature, and the Williamson reaction of the depro-
tected phenol 10 with 3-chloro-N,N-diethylpropylamine produced 3, a viscous liquid, in 85% yield
(Scheme 2). The 4-fluoro isomer 4 was prepared in the same way.

HETEROCYCLES, Vol. 80, No. 1, 2010
665
F
O
F
I
OMe
Cl
Pd(OAc) , K CO
SnCl
2
2
3
O
4
PEG 4000-MeOH 1:1
50°C, 30 min
CH Cl , 0°C, 30 min
30°C, 2 h
2
2
O
B(OH)2
O
O
OMe
OMe
6
8
94%
9
85%
F
F
1. NaOMe,
MeOH, toluene
2. Cl(CH ) NEt
BBr
O
O
3
2 3
2
CH Cl , –78°C
rt, 15 h
toluene,
reflux, 6 h
2
2
O
O
O(CH2)3NEt2
OH
10
83%
3
85%
Scheme 2
The synthesis can be modified, starting with phenol 11 and carrying the acylation reaction in the last step
(Scheme 3). Thus, cleavage of the methoxy group of 8 gave phenol 11 in 90% overall yield from 2-
benzofuranylboronic acid. An alternate synthesis from 2-(4-nitrophenyl)benzofuran by the reduction –
diazotization – hydrolysis sequence afforded 11 in 62% yield.13
1. KOH, EtOH
2. Cl(CH ) NEt
BBr
2 3
2
3
EtOH,
reflux, 20 h
CH Cl , –78°C
rt, 15 h
2
2
O
O
O
OMe
O(CH2)3NEt2
OH
8
11
90%
12
82%
F
1. AlCl , CH Cl
2
3
2
O
2. 2-FC H COCl
6
4
CH Cl , reflux,
18 h
2
2
O
O(CH2)3NEt2
3
69%
Scheme 3
Both steps, the Williamson and Friedel-Crafts reactions, under the conditions indicated, gave lower yields
as compared to the route shown on Scheme 2. Acylation of 12 in the presence of aluminum chloride (2.2

666
HETEROCYCLES, Vol. 80, No. 1, 2010
molar equivalents) requires a larger amount of Lewis acid, longer time, and higher temperature, as com-
pared to the acylation of 8 in the presence of tin(IV) chloride. The final products 3 and 5, prepared ac-
cording to Scheme 3, were purified by column chromatography on silica gel, eluent ethyl acetate-
triethylamine 100:1.
In conclusion, the Suzuki cross-coupling reaction, providing a high yield access to the key intermediate 8
under mild conditions from readily available materials, makes the approach shown on Scheme 2 conve-
nient and efficient. Hydrochlorides of aminoketones 3–5 were investigated for acetylcholinesterase inhi-
bitory activity, using purified enzyme from bovine erythrocytes employing spectrophotometry,20 but
found to be not effective in the range of 10-9–10-4 M. -Amyloid aggregation inhibitory activity is cur-
rently under investigation.
EXPERIMENTAL
2-(4-Methoxyphenyl)benzofuran (8). 4-Iodoanisole (1.87 g, 8 mmol), potassium carbonate (1.84 g, 13.3
mmol), and 6 (1.63 g, 10 mmol) were added to a mixture of MeOH (20.00 g) and polyethylene glycol
4000 (20.00 g) at 50 °C under argon. After 10 min stirring, palladium acetate (10 mg) was added and the
mixture was stirred for 1 h at this temperature. MeOH was removed on a rotary evaporator, water (100
mL) was added, precipitated solid was filtered off and dissolved in Et2O. The filtrate was extracted with
Et2O (2x50 mL). The ethereal solutions were combined, washed with 3M aqueous NaOH (25 mL), satu-
rated brine (20 mL), and dried with anhydrous magnesium sulfate. Solvent was removed and the product
was crystallized from n-hexane, 1.69 g, 94%, mp 153–154 °C (Lit.,21 152–154 °C). 1H NMR (300 MHz,
CDCl3),  (ppm) 3.87 (s, 3H, CH3), 6.90 (d, J = 0.6 Hz, 1H, CH), 6.96–7.01 (AA’ spin system, 2H, CH),
7.21 (td, J = 7.2, 1.6 Hz, 1H, CH), 7.26 (td, J = 7.2, 1.8 Hz, 1H, CH), 7.51 (ddd, J = 7.2, 1.8, 0.6 Hz, 1H,
CH), 7.56 (ddd, J = 7.2, 1.8, 0.6 Hz, 1H, CH), 7.78–7.83 (BB’ spin system, 2H, CH). 13C NMR (75 MHz,
CDCl3),  (ppm) 55.31 (CH3), 99.65 (CH), 110.96 (CH), 114.22 (2CH), 120.54 (CH), 122.80 (CH),
123.31 (C), 123.70 (CH), 126.39 (2CH), 129.47 (C), 154.64 (C), 156.03 (C), 159.95 (C).
2-[4’-(3-Diethylaminopropoxy)phenyl]-3-(2-fluorobenzoyl)benzofuran (3). 1H NMR (300 MHz,
CDCl3)  (ppm) 1.04 (t, J = 7.2 Hz, 6H, CH3), 1.91 (quintet, J = 6.3 Hz, 2H, CH2), 2.55 (q, J = 7.2, 4H,
NCH2), 2.59 (t, J = 6.3 Hz, 2H, NCH2), 3.90 (t, J = 6.3 Hz, 2H, OCH2), 6.74–6.80 (AA’ spin system, 2H,
CH), 6.88 (ddd, J = 10.2, 8.4, 0.9 Hz, 1H, CH), 7.09 (td, J = 7.5, 1.2 Hz, 1H, CH), 7.28 (td, J = 7.5, 1.2
Hz, 1H, CH), 7.31–7.40 (m, 2H, CH), 7.53–7.60 (m, 4H, CH), 7.74 (ddd, J = 7.2, 1.2, 0.9 Hz, 1H, CH).
13C NMR (75 MHz, CDCl3)  (ppm) 11.81 (2CH3), 26.93 (CH2), 47.04 (2NCH2), 49.19 (NCH2), 66.38
(OCH2), 111.01 (CH), 114.09 (2CH), 116.10 (d, JCF = 21.8 Hz, 2CH), 116.28 (C), 121.46 (C), 121.53
(CH), 124.05 (CH), 124.07 (d, JCF = 4.5 Hz, CH), 125.05 (CH), 127.64 (C), 128.21 (d, JCF = 12.7 Hz, C),

HETEROCYCLES, Vol. 80, No. 1, 2010
667
130.63 (2CH), 130.82 (d, JCF = 2.20 Hz, CH), 133.35 (d, JCF = 8.6 Hz, CH), 153.65 (C), 160.36 (d, JCF
=
254.4 Hz, C), 160.54 (C), 161.18 (d, JCF = 1.4 Hz, C), 188.31 (CO). IR: 1640 cm-1 (C=O); HRMS:
C28H28FNO3 m/z [M+1]+ Calcd. 446.2126; Found 446.2124. Anal. Calcd for C28H28FNO3: C 75.48%; H
6.33%; N 3.14%. Found C 75.65%; H 6.38%; N 3.44%.
2-[4’-(3-Diethylaminopropoxy)phenyl]-3-(4-fluorobenzoyl)benzofuran (4). Hydrochloride (4·HCl),
1
mp 149–152 °C. H NMR (300 MHz, CDCl3)  (ppm) 1.39 (t, J = 7.2 Hz, 6H, CH3), 2.29-2.40 (m, 2H,
CH2), 3.13 (q, J = 7.2, 4H, NCH2), 3.18 (t, J = 8.1 Hz, 2H, CH2), 4.05 (t, J = 5.7 Hz, 2H, CH2), 6.73-6.81
(AA’ spin system, 2H, CH), 6.93-7.03 (AA’ spin system, C6H4F, 2H, CH), 7.22 (td, J = 7.5, 0.9 Hz, 1H,
CH), 7.32 (td, J = 8.1, 1.2 Hz, 1H, CH), 7.47 (dd, J = 7.5, 0.6 Hz, 1H, CH), 7.53 (dd, J = 8.1, 0.4 Hz, 1H,
13
CH), 7.55-7.61 (BB’ spin system, 2H, CH), 7.78-7.86 (BB’ spin system, C6H4F, 2H, CH). C NMR (75
MHz, CDCl3)  (ppm) 8.49 (2CH3), 23.59 (CH2), 46.62 (2CH2), 48.97 (CH2), 64.79 (CH2), 111.05 (CH),
114.22 (2CH), 114.75 (C), 115.50 (d, JCF = 21.7 Hz, 2CH), 121.08 (CH), 122.36 (C), 123.75 (CH),
125.09 (CH), 128.26 (C), 130.03 (2CH), 132.33 (d, JCF = 9.36 Hz, 2CH), 134.15 (d, JCF = 2.87 Hz, C),
153.51 (C), 157.60 (C), 159.32 (C), 165.57 (d, JCF = 254.95 Hz, C), 190.59 (CO). 4: Anal. Calcd for
C28H28FNO3: C 75.48%; H 6.33%; N 3.14%. Found C 75.40%; H 6.30%; N 3.09%. IR: 1643 cm-1;
HRMS: C28H28FNO3 m/z [M+1]+ Calcd. 446.2126; Found 446.2123.
1
2-[4’-(3-Diethylaminopropoxy)phenyl]-3-(4-trifluoromethylbenzoyl)benzofuran (5). H NMR (300
MHz, CDCl3)  (ppm) 1.03 (t, J = 7.2 Hz, 6H, CH3), 1.93 (quintet, J = 6.6 Hz, 2H, CH2), 2.53 (q, J = 7.2,
4H, 2NCH2), 2.58 (t, J = 6.6 Hz, 2H, NCH2), 3.99 (t, J = 6.3 Hz, 2H, OCH2), 6.76–6.81 (AA’ spin system,
2H, CH), 7.28 (ddd, J = 7.5, 7.2, 1.5 Hz, 1H, CH), 7.37 (ddd, J = 8.1, 7.5, 1.5 Hz, 1H, CH), 7.51-7.58
(BB’ spin system, 2H, CH), 7.55-7.59 (m, 4H, CH), 7.61 (ddd, J = 7.2, 0.9, 0.6 Hz, 1H, CH), 7.87 (ddd, J
= 8.1, 0.8, 0.6 Hz, 1H, CH). 13C NMR (75 MHz, CDCl3)  (ppm) 11.72 (2CH3), 26.88 (CH2), 46.99
(2NCH2), 49.19 (NCH2), 66.45 (OCH2), 111.14 (CH), 114.42 (2CH), 114.46 (C), 121.36 (CH), 123.57 (q,
JCF = 271.2 Hz, CF), 124.01 (CH), 125.23 (CH), 125.28 (q, JCF = 3.5 Hz, 2CH), 128.13 (C), 129.93
(2CH), 130.36 (2CH), 133.88 (q, JCF = 32.4 Hz, C), 140.58 (C), 141.05 (C), 153.71 (C), 159.68 (C),
160.70 (C), 191.09 (CO). Anal. Calcd for C29H28F3NO3: C 70.29%; H 5.69%; N 2.83%. Found C 70.17%;
H 5.50%; N 3.06%. IR: 1645 cm-1 (C=O); HRMS: C29H28F3NO3 m/z [M+1]+ Calcd. 496.20941; Found
496.20857.
ACKNOWLEDGEMENTS
Financial support from the Ministry of Higher Education, Warsaw, grant PBZ-KBN 126/T09/2004 is ac-
knowledged.

668
HETEROCYCLES, Vol. 80, No. 1, 2010
REFERENCES
1. E. D. Robertson and L. Mucke, Science, 2006, 314, 781.
2. K. Blennow, M. J. de Leon, and H. Zetterberg, Lancet, 2006, 368, 387.
3. T. Luhrs, C. Ritter, M. Adrian, D. Riek-Loher, D. Bohrmann, H. Dobeli, D. Schubert, and R. Riek,
Proc. Natl. Acad. Sci. U.S.A., 2005, 102, 17342.
4. J. Hardy and D. J. Selcoe, Science, 2002, 297, 353.
5. G. H. Cocolas and S. I. Cutler, in ‘Organic Medicinal and Pharmaceutical Chemistry,’ 11th ed., ed. by
J. H. Block, J. M. Biele, Lippincott Williams & Wilkins, Philadelphia, 2004, 566; E. J. Corey, B.
Czako, and L. Kürti, ‘Molecules and Medicine,’ J. Wiley, Hoboken, 2007, 225.
6. R. A. Hansen, G. Gartlehner, K. N. Lohr, and D. I. Kaufer, Drugs Aging, 2007, 24, 155; E. I. Solntse-
va, J. V. Bukanova, E. V. Marchenko, A. V. Rossokhin, and N. G. Skrebitsky, Cell. Mol. Neurobiol.,
2009, 29, 219; H. Sugimoto, H. Ogura, Y. Arai, Y. Iimura, and Y. Yamanishi, Jpn. J. Pharmacol.,
2002, 89, 7.
7. F. Belluti, L. Piazzi, A. Bisi, S. Gobi, M. Bartolini, A. Cavalli, P. Valenti, and A. Rampa, Eur. J. Med.
Chem., 2009, 44, 1341; R. Sheng, Y. Xu, Ch. Hu, J. Zhang, X. Lin, J. Li, B. Yang, Q. He, and Y. Hu,
Eur. J. Med. Chem., 2009, 44, 7.
8. C. A. Ross and M. A. Poirier, Nat. Med., 2004, S10; D. Shaw, J. Best, K. Dinnell, A. Nadin, M.
Sherman, C. Pattison, J. Peachey, M. Reilly, B. Williams, J. Wrigley, and T. Harrison, Bioorg. Med.
Chem. Lett., 2006, 16, 3073.
9. L. J. Twyman and D. Allsop, Tetrahedron Lett., 1999, 40, 9383.
10. D. Allsop, G. Gibson, I. K. Martin, S. Moore, S. Turnbull, and L. J. Twyman, Bioorg. Med. Chem.
Lett., 2001, 11, 255.
11. S. Rizzo, C. Riviere, L. Piazzi, A. Bisi, S. Gobi, M. Bartolini, V. Andrisano, F. Morroni, A. Tarazzi,
J.-P. Monti, and A. Rampa, J. Med. Chem., 2008, 51, 2883.
12. L. M. Brenner and Ch. K. Brush, US Pat. 4,001,426 (1977). Chem. Abstr., 1977, 87, 39262h.
13. O. Dann, J. Ruff, and H. Griessmeier, Liebigs Ann. Chem., 1984, 409.
14. J. Yates and R. S. Airs, GB Pat. 814647, 1959. Chem. Abstr., 1960, 54, 8851h.
15. Y. Yamamoto, M. Takizawa, X.-Q. Yu, and N. Miyaura, Angew. Chem. Int. Ed., 2008, 47, 928.
16. J.-H. Li and W.-J. Liu, Org. Lett., 2004, 6, 2809.
17. L. Liu, Y. Zhang, and Y. Wang, J. Org. Chem., 2005, 70, 6122.
18. I. R. Baxendale, Ch. M. Gryffiths-Jones, S. V. Ley, and G. K. Tranmer, Chem. Eur. J., 2006, 12, 4407.
19. R. H. Taylor and F.-X. Felpin, Org. Lett., 2007, 9, 2911.
20. G. L. Ellman, D. Courtney, V. Andres, and R. M. Featherstone, Biochem. Pharmacol., 1961, 7, 88.
21. M. Csekei, Z. Novak, and A. Kotschy, Tetrahedron, 2008, 64, 8992.